This integrative network indicated that the antitumor effect of SR on HCC might be attributed to the active components (wogonin, oroxylin A, and baicalein) acting on candidate protein targets (PTGS2, HSP90AA1, AR, TP53, GTPase KRas (KRAS), phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform (PIK3CG), and CCND1) that regulate key pathways (pathways in cancer, proteoglycans or microRNAs in cancer, hepatitis B, and PI3K-Akt signaling pathway) to affect the survival of HCC cells. The gene discussed is KRAS; the disease is hepatocellular carcinoma.